74 results
8-K
EX-99.1
WINT
Windtree Therapeutics Inc
21 Sep 10
Discovery Labs Appoints Thomas C. Hoy as Vice President of Manufacturing Operations
12:00am
responsible for leadership and management of all Discovery Labs’ KL4 surfactant product manufacturing, global supply chain, and pharmaceutical development … Biologics Supply Chain, where he was responsible for a 400-person bulk biologic production facility for the manufacturing of a finished product
8-K
EX-99.1
WINT
Windtree Therapeutics Inc
5 Dec 22
Other Events
7:48am
or disruption in supply chain; the success and advancement of the clinical development programs for istaroxime and the Company’s other product candidates … and/or other countries which could have an adverse impact on the Company’s operations, including through disruption in supply chain or access
8-K
EX-99.1
WINT
Windtree Therapeutics Inc
23 Aug 22
Windtree Therapeutics Announces KL4 Surfactant and AEROSURF® Global License Agreement
8:30am
adverse impact on the Company’s clinical trials, clinical trial timelines or disruption in supply chain; the success and advancement of the clinical … an adverse impact on the Company’s operations, including through disruption in supply chain or access to potential international clinical trial sites
8-K
EX-99.1
WINT
Windtree Therapeutics Inc
15 Mar 22
Windtree Completes Enrollment of Phase 2 Study of Istaroxime in Early Cardiogenic Shock
7:04am
, including any adverse impact on the Company's clinical trials, clinical trial timelines or disruption in supply chain; the success and advancement … on the Company's clinical trials and clinical trial timelines, in particular with respect to clinical trial sites in Russia, or disruption in supply chain
8-K
EX-99.1
WINT
Windtree Therapeutics Inc
20 Apr 22
Windtree Announces Positive Topline Results from Its
7:07am
or disruption in supply chain; the success and advancement of the clinical development programs for istaroxime, KL4 surfactant and the Company's other … countries which could have an adverse impact on the Company's operations, including through disruption in supply chain or access to potential international
8-K
EX-99.1
3io56o5
5 May 22
Windtree Therapeutics Reports First Quarter 2022 Financial Results and Provides Key Business Updates
4:04pm
8-K
EX-99.1
e5sc6qvm13knav08
11 Aug 22
Windtree Therapeutics Reports Second Quarter 2022 Financial Results and Provides Key Business Updates
4:06pm
8-K
EX-99.1
lnkavzu3s7
9 Nov 23
Windtree Therapeutics Reports Third Quarter 2023 Financial Results and Provides Key Business Updates
4:21pm
8-K
EX-99.1
2bo8 va377l6de3twgd
23 May 22
The study met its primary endpoint of improved systolic blood pressure (SBP) profile at 6 hours
4:01pm
8-K
EX-99.1
5e36e3jburw
15 May 23
Windtree Therapeutics Reports First Quarter 2023 Financial Results and Provides Key Business Updates
4:24pm
8-K
EX-99.1
lhyvfvrf sot
7 Aug 23
Windtree Therapeutics Reports Second Quarter 2023 Financial Results and Provides Key Business Updates
4:02pm
8-K
EX-99.1
ks2a8og10u1x
14 Nov 22
Windtree Therapeutics Reports Third Quarter 2022 Financial Results and Provides Key Business Updates
7:33am
8-K
EX-99.1
02lhi 74t72b
31 Mar 22
Windtree Therapeutics Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Key Business Updates
7:05am
8-K
EX-99.1
5r1x 2ozhgjtywais
24 Oct 12
Other Events
12:00am
8-K
mg67yws8s4ouwec2
25 Aug 10
Departure of Directors or Certain Officers
12:00am
8-K
EX-99.1
amn wk9z13a0
29 Apr 20
Windtree Therapeutics Announces Reverse Stock Split
5:29pm
8-K
EX-99.1
h2tqdxoop9z7j
22 May 20
Windtree Therapeutics Announces Pricing of $20.0 Million Public Offering and Uplisting to the Nasdaq Capital Market
5:22pm
8-K
EX-99.1
tzjtn ymptuoo0f
31 Jan 24
Windtree Therapeutics Announces Engagement of Strategic Advisor to Support Assessment of Strategic Alternatives
8:00am
8-K
EX-99.2
hf5deu1wnod1swhy6nc
22 May 20
Windtree Therapeutics Announces Pricing of $20.0 Million Public Offering and Uplisting to the Nasdaq Capital Market
5:22pm
8-K
EX-99.1
k1tfi5oe9fbpda
1 Oct 20
Windtree Announces First Patient Dosed in Phase 2 Study of Istaroxime for the Acute Treatment of Early Cardiogenic Shock in Heart Failure Patients
7:36am